<DOC>
	<DOCNO>NCT02194881</DOCNO>
	<brief_summary>The purpose study determine whether treatment Ivacaftor remain effective safe patient cystic fibrosis ( least one G551D CFTR mutation ) real life setting , drug approve Health authority .</brief_summary>
	<brief_title>Ivacaftor French Patients With Cystic Fibrosis G551D Mutation</brief_title>
	<detailed_description>The aim study : 1. describe treat population initiation treatment , 2. evaluate clinical parameter year Ivacaftor start , initiation treatment least one year treatment , June 2014 . 3. evaluate tolerance safety treatment .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>French patient CF age 6 old homozygous heterozygous G551D mutation Treated Ivacaftor First prescription Ivacaftor June 1st 2013 ( include patient randomize VX770 clinical trial ) CF patient young 6 year old CF patient receive lung transplantation CF patient without G551D mutation .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>CFTR</keyword>
	<keyword>G551D mutation</keyword>
	<keyword>Novel treatment</keyword>
	<keyword>Potentiator</keyword>
	<keyword>Ivacaftor</keyword>
</DOC>